Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Viani Evohaler to Serroflo pMDI in stable persistent asthma
2015-004455-52Phase 4Active
- Sponsor
- Cipla
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of salmeterol + fluticasone in asthma (2 arms), sponsored by Cipla. Primary endpoint: Overall asthma control. Started Dec 2015; status: active.
02
Drugs
salmeterol + fluticasone
03
Conditions
asthma
Beyond the preview
Go deeper on 2015-004455-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004455-52.